Drugs / DC/myeloma fusions
DC/myeloma fusions
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03782064 | Feb 2019 → Jan 2021 | plasma cell myeloma | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC/myeloma fusions | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03782064 ↗ |
| Known as | DC/MM vaccine | “This research study is studying a cancer vaccine called Dendritic Cell/MM Fusion vaccine (DC/MM vaccine) in combination with nivolumab, as a possible treatment for multiple...” NCT03782064 ↗ |
| Known as | Dendritic Cell/MM Fusion vaccine | “This research study is studying a cancer vaccine called Dendritic Cell/MM Fusion vaccine (DC/MM vaccine) in combination with nivolumab, as a possible treatment for multiple...” NCT03782064 ↗ |
| Modality | Vaccine | “The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing those unique markers.” NCT03782064 ↗ |